Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
BNTC Stock Chart & Stats
$11.42
<$0.01(0.09%)
At close: 4:00 PM EST
$11.42
<$0.01(0.09%)
Day’s Range― - ―
52-Week Range$9.85 - $17.15
Previous CloseN/A
Volume10.71K
Average Volume (3M)174.24K
Market Cap
$392.33M
Enterprise Value$111.94M
Total Cash (Recent Filing)$188.79M
Total Debt (Recent Filing)$987.00K
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 18, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding34,354,336
10 Day Avg. Volume88,089
30 Day Avg. Volume174,244
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue201.33
Enterprise Value/Gross Profit-1.70K
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$32.00Price Target Upside180.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInterim results reported that all completers from the initial cohort met the trial's predefined responder criteria, suggesting a strong early signal of clinically meaningful improvement in swallowing function.
Financial RunwayAnalyst views the company's cash position as sufficient to fund the BB-301 clinical program and initiate a registrational trial, reducing the immediate need for additional financing to advance development.
Regulatory PathwayAnalyst notes regulatory alignment with the FDA on pivotal trial design and endorsement of a proprietary responder index by key opinion leaders, which supports a clearer route toward potential approval for BB-301.
Bears Say
Data Reproducibility RiskThe current positive findings are based on a small patient group, so additional data will be required to confirm the results and there is a risk that larger cohorts may not replicate early outcomes.
Limited Clinical SampleOnly a small number of patients have been dosed, which limits the available clinical evidence for BB-301 and constrains confidence in the durability and generalizability of the observed effects.
Operating CostsAnalyst observes that rising research and administrative expenses, driven by higher share-based compensation, are increasing operating cost pressure and could raise cash burn.
Benitec Biopharma News
BNTC FAQ
What was Benitec Biopharma Ltd’s price range in the past 12 months?
Benitec Biopharma Ltd lowest stock price was $9.85 and its highest was $17.15 in the past 12 months.
What is Benitec Biopharma Ltd’s market cap?
Benitec Biopharma Ltd’s market cap is $392.33M.
When is Benitec Biopharma Ltd’s upcoming earnings report date?
Benitec Biopharma Ltd’s upcoming earnings report date is May 18, 2026 which is in 35 days.
How were Benitec Biopharma Ltd’s earnings last quarter?
Benitec Biopharma Ltd released its earnings results on Feb 12, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.223 by -$0.037.
Is Benitec Biopharma Ltd overvalued?
According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued.
Does Benitec Biopharma Ltd pay dividends?
Benitec Biopharma Ltd pays a Notavailable dividend of $0.765 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma Ltd dividends here
What is Benitec Biopharma Ltd’s EPS estimate?
Benitec Biopharma Ltd’s EPS estimate is -0.28.
How many shares outstanding does Benitec Biopharma Ltd have?
Benitec Biopharma Ltd has 34,354,336 shares outstanding.
What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?
Benitec Biopharma Ltd reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.223. Following the earnings report the stock price went down -2.661%.
Which hedge fund is a major shareholder of Benitec Biopharma Ltd?
Currently, no hedge funds are holding shares in BNTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Benitec Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (180.21% Upside)
$32.00 (180.21% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.35%
12-Months-Change
Fundamentals
Return on Equity
-38.92%
Trailing 12-Months
Asset Growth
141.16%
Trailing 12-Months
Company Description
Benitec Biopharma Ltd
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
BNTC Stock 12 Month Forecast
Average Price Target
$32.00
▲(180.21% Upside)
Technical Analysis
Tvardi Therapeutics
―
Assembly Biosciences
―
Rocket Pharmaceuticals
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
5.76% Insiders
7.28% Mutual Funds
61.38% Other Institutional Investors
19.34% Public Companies and
Individual Investors